Anti-angiogenic properties of chemopreventive drugs: fenretinide as a prototype.
Recent Results Cancer Res. 2009;181:71-6
Authors: Sogno I, Venè R, Sapienza C, Ferrari N, Tosetti F, Albini A
Several cancer chemopreventive agents have been demonstrated to exert antiangiogenic effects. Blocking tumor angiogenesis, a process critical for tumor mass expansion and metastasis, represents an intriguing approach not only to cancer therapy, but also to cancer chemoprevention. We found that angiogenesis is a common and key target of many chemopreventive molecules, where they most likely suppress the angiogenic switch in premalignant tumors, a concept we termed "angioprevention." In this manuscript we use as an example the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR), a molecule with confirmed clinical applications in *** cancer adjuvant therapy to prevent cancer recurrence and under evaluation in neuroblastoma and glioblastoma treatment.
PMID: 19213559 [PubMed - in process]